Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients
Gabriela Jiménez-Valerio(Institut d'Investigació Biomédica de Bellvitge), Oriol Casanovas(Institut Català d'Oncologia), María Ochoa-de-Olza(Institut Català d'Ornitologia), Mariona Graupera(Josep Carreras Leukaemia Research Institute), Stefano Indraccolo(University of Padua), Francesc Viñals(Bellvitge University Hospital), Xavier García del Muro(Institut Català d'Oncologia), Nicklas Bassani(Institut d'Investigació Biomédica de Bellvitge), Cristina Suárez(Complejo Hospitalario de Salamanca), Joan Carles(Vall d'Hebron Hospital Universitari), Mar Martínez‐Lozano(Institut d'Investigació Biomédica de Bellvitge), August Vidal(Bellvitge University Hospital)
Cited by 119
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
|Cancer Cell|2009|2.3k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k